+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Drugs Market Research Reports

From
From
Epithelial Ovarian Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Epithelial Ovarian Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
HER2Negative Metastatic Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

HER2Negative Metastatic Breast Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
From
HER2-Positive Early Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

HER2-Positive Early Breast Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Thymidine Kinase 2 Deficiency (TK2D) - Pipeline Insight, 2024 - Product Thumbnail Image

Thymidine Kinase 2 Deficiency (TK2D) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Advanced Breast Cancer in Premenopausal Women - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Breast Cancer in Premenopausal Women - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Neo Antigen T-cell Therapy - Pipeline Insight, 2024 - Product Thumbnail Image

Neo Antigen T-cell Therapy - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
T cell therapy - Pipeline Insight, 2024 - Product Thumbnail Image

T cell therapy - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Advanced ovarian cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced ovarian cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 210 Pages
  • Global
From
ESR1-Mutated Metastatic Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

ESR1-Mutated Metastatic Breast Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Breast Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Metastatic Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 100 Pages
  • Global
From
Ovarian Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Ovarian Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 450 Pages
  • Global
From
Brain Metastasis from Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Brain Metastasis from Breast Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
From
Casein Kinase 2 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Casein Kinase 2 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 120 Pages
  • Global
From
Pim Kinase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Pim Kinase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more